Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Proglumetacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 17/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proglumetacin SCHEMBL1650599 | 1.00 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL19642980 | 1.00 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL27106 | 0.97 | PTGS2 (0.59) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL29384391 | 0.97 | PTGS2 (0.59) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL2070226 | 0.94 | PTGS2 (0.55) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL28086382 | 0.94 | PTGS2 (0.55) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL13724384 | 0.89 | PTGS2 (0.49) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL5077578 | 0.89 | PTGS2 (0.57) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL4094289 | 0.88 | PTGS2 (0.52) | PTGS2 | |
| Proglumetacin SCHEMBL5482765 | 0.87 | PTGS2 (0.47) | PTGS2HTR1APKMPTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 971 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374478-B1 | NSAID-DISACCHARIDE INCLUSION COMPLEXES FOR ALLEVIATING DAMAGE TO THE GASTROINTESTINAL MUCOSA | NEXT 21 K K (JP) | 2017-08-23 | — | — | EP | claimed |
| US-9452180-B2 | NSAIDs-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof | NEXT21 K.K. (JP) | 2016-09-27 | — | — | US | claimed |
| US-20140323429-A1 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF | NEXT21 K.K. (JP) | 2014-10-30 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20110301116-A1 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2011-12-08 | — | — | US | claimed |
| EP-2374478-A1 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF | Next 21 K.K. (JP) | 2011-10-12 | — | — | EP | claimed |
| WO-2008069546-A1 | ORAL ADMINISTRATIVE PREPARATION FOR TREATING CARDIOVASCULAR SYSTEM DISEASE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2008-06-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-7069880-A | — | — | None | — | — | JP | disclosed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-26 | — | — | US | disclosed |
| EP-0140709-A2 | 5-Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0140684-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0138481-A2 | Leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| EP-0136893-A2 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1985-04-10 | — | — | EP | disclosed |
| EP-0123541-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| EP-0123543-A1 | Leukotriene antagonists, their production and use and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | HTR1A 1697/4885PTGS2 2731/4885PKM 2805/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | HTR1A 202/4885PTGS2 200/4885PKM 4558/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | HTR1A 2808/4885PTGS2 3198/4885PKM 4501/4885 |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | HTR1A 3150/4885PTGS2 3421/4885PKM 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.